The startup develops psychedelics-based neuromodulators by repurposing psychoactive natural products to create therapies for cognitive, mood, and substance use disorders. This approach provides clinicians with targeted treatment options to enhance mental health outcomes.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for cognitive, mood, and substance use disorders often lack specificity and can produce unwanted side effects, such as hallucinations, limiting their applicability and patient adherence. This creates a need for more targeted and tolerable therapeutic options to address these complex neurological conditions.
Solution
Psilera is developing a new generation of neuroplastogens, derived from psychoactive natural products, engineered to provide therapeutic benefits without the hallucinogenic effects. The company's proprietary Third Eye™ drug screening platform uses computational chemistry, data science, and biomolecular physics to analyze compound interactions with the brain, optimizing drug candidates before in-vivo testing. This approach allows for the creation of patient-centric therapies that can be administered at home, improving accessibility and adherence. Psilera's lead candidate, PSIL-006, is being developed for Frontotemporal Dementia (FTD) and has demonstrated efficacy in preclinical studies without treatment-limiting side effects.
Target Audience
The primary target audience includes individuals suffering from neurological conditions such as Frontotemporal Dementia (FTD), as well as clinicians seeking more targeted and tolerable treatment options for cognitive, mood, and substance use disorders.
Features
- Proprietary Third Eye™ drug screening platform for in silico analysis of compound-brain interactions
- Focus on creating non-hallucinogenic neuroplastogens for improved patient tolerability
- PSIL-006, a lead drug candidate targeting Frontotemporal Dementia (FTD)
- Serotonergic compound families with potential for treating various neurological conditions
- Preclinical data demonstrating efficacy of PSIL-006 in reducing FTD-related symptoms
- Patents filed covering novel compounds